Eshima D, Fauconnier T, Eshima L, Thornback J R
Syncor International Inc., Erie, CO 80516, USA.
Semin Nucl Med. 2000 Jan;30(1):25-32. doi: 10.1016/s0001-2998(00)80059-8.
The recognition of the importance of lymphoscintigraphy for identification of the sentinel lymph nodes in melanoma and breast cancer plays a significant role in the clinical management of these patients. The widespread clinical acceptance of this technique and the lack of an agreement on which radiopharmaceutical agent has the most ideal properties has resulted in a wide variety of agents being used clinically with other agents under investigation or development. This article reviews some of the physical properties that a radiopharmaceutical agent should possess and discusses in depth commonly used agents and lists some agents under development. This article also discusses the dosimetry and biological effects various radiopharmaceutical agents have for lymphoscintigraphy in melanoma and breast cancer patients. In view of the lack of a consensus agreement on which radiopharmaceutical agent will provide the optimal clinical information this article will provide an overview of potentially useful radiopharmaceutical agents and radiation dosimetry considerations.
认识到淋巴闪烁显像在识别黑色素瘤和乳腺癌前哨淋巴结方面的重要性,对这些患者的临床管理具有重要意义。该技术在临床上得到广泛认可,且对于哪种放射性药物具有最理想特性尚无共识,这导致临床上使用了多种药物,同时还有其他药物正在研究或开发中。本文回顾了放射性药物应具备的一些物理特性,深入讨论了常用药物,并列出了一些正在开发的药物。本文还讨论了各种放射性药物对黑色素瘤和乳腺癌患者淋巴闪烁显像的剂量学和生物学效应。鉴于对于哪种放射性药物能提供最佳临床信息缺乏共识,本文将概述潜在有用的放射性药物及辐射剂量学考量。